Having a meeting with them in Providence next week. It should be very interesting to hear CEO present to Physicians. Even though the information to date is already public it is much more digestible when presented in person.
I am hoping that Phase II B starts in the fall. That would give a timeline that could have good end point data by the end of Q4 or Q1 2018. That is a pretty short time frame to be invested in a Bio and get pretty good endpoints on efficacy and safety,
If Naurex total was 600 mil in cash and a little over a bil on the back end in potential milestone payouts; and has to be taken intravenously, what type of multiple would be placed on an oral medication.
There will obviously be more dilution in funding II, but comparing apples to apples as it stands now
VTGN would be 30 times higher in cash $60.00
VTGN would have back end payments of $100.00
There will be dilution and these are what if's, but whatever dilution occurs forward should be more than offset considering VTGN's indication is oral which could command an unbelievable multiple.
Next, consider the other indications for pain, Parkinson's ect. One of the reasons why it is a good idea trying to find a buyer or strategic partner after Phase II is it allows the buyer to tailor the NDA and spin off indications the way its best suits their model.
The stem cell component is interesting as well and there was talk of possibly spinning that off to another company as a dividend. Just rumor as of now though.
